Leica Microsystems

Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.

Companion diagnostics developed under the deal will be based on RNAscope and immunohistochemistry technology.

Leica Biosystems aims to create a companion test for seribantumab, an investigational human monoclonal antibody used in combination therapy to treat cancer.

The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.

Affymetrix this week reported a slight uptick in its second-quarter revenues, which increased 3 percent to $66.4 million from $64.7 million in the year-ago period, beating the average analyst estimate of $65.6 million.

NEW YORK (GenomeWeb News) – Affymetrix and Leica Microsystems today announced a deal to automate Affymetrix's QuantiGene View RNA ISH Tissue Assay on the Leica Bond RX staining platform for research applications.

BG Medicine this week appointed Eric Bouvier as president and CEO. He replaces Pieter Muntendam, who has moved to the role of executive vice president and chief medical officer.

The alliance will combine Leica's automated confocal instruments with Definiens' analysis software.

Abbott's PathVysion FISH assay will be used to develop the test on Leica's BOND platform.

Genetix will operate as a separate business unit within Danaher subsidiary Leica Microsystems.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.